Intravenous, non-viral RNAi gene therapy of brain cancer
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) has the potential to knock down oncogenes in cancer, including brain cancer. However, the therapeutic potential of RNAi will not be realised until the rate-limiting step of delivery is solved. The development of RNA-based therapeutics is not practical, due to the instability of RNA in vivo. However, plasmid DNA can be engineered to express short hairpin RNA (shRNA), similar to endogenous microRNAs. Intravenous, non-viral RNAi-based gene therapy is enabled with a new gene-targeting technology, which encapsulates the plasmid DNA inside receptor-specific pegylated immunoliposomes (PILs). The feasibility of this RNAi approach was evaluated by showing it was possible to achieve a 90% knockdown of brain tumour-specific gene expression with a single intravenous injection in adult rats or mice with intracranial brain cancer. The survival of mice with intracranial human brain cancer was extended by nearly 90% with weekly intravenous injections of PILs carrying plasmid DNA expressing a shRNA directed against the human epidermal growth factor receptor. RNAi-based gene therapy can be coupled with gene therapy that replaces mutated tumour suppressor genes to build a polygenic approach to the gene therapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 1×
“(2004) 4(7) Disregarding the concerns related to immunogenicity [8] and insertional mutagenesis caused by chromosomal integration with viruses such as retrovirus [9] or adeno-associated virus (AAV) [10], viral vectors are not effective in brain cancer after intravenous administration because they do not cross the BBB.”
BackgroundImmune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“(2004) 4(7) Disregarding the concerns related to immunogenicity [8] and insertional mutagenesis caused by chromosomal integration with viruses such as retrovirus [9] or adeno-associated virus (AAV) [10], viral vectors are not effective in brain cancer after intravenous administration because they do not cross the BBB.”
BackgroundAAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392 · cited 3×
“NAKAI H, MONTINI E, FUESS S et al.: AAV serotype 2 vectors preferentially integrate into active genes in mice.”
BackgroundZhang, Y., Calon, F., Zhu, C., Boado, R. J., & Pardridge, W. M. (2003) · Human Gene Therapy · doi:10.1089/10430340360464660 · Cited by 194
Self-citation
Cited by
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function
Ying, S.-Y., Chang, D. C., & Lin, S.-L. (2008) · Molecular Biotechnology · doi:10.1007/s12033-007-9013-8 · Cited by 323
Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)
Ulbrich, K., Knobloch, T., & Kreuter, J. (2011) · Journal of Drug Targeting · doi:10.3109/10611861003734001 · Cited by 259
Wesolowska, A., Kwiatkowska, A., Slomnicki, L., Dembinski, M., Master, A., Sliwa, M., Franciszkiewicz, K., Chouaib, S., & Kaminska, B. (2008) · Oncogene · doi:10.1038/sj.onc.1210683 · Cited by 258
Zhang, Y., Calon, F., Zhu, C., Boado, R. J., & Pardridge, W. M. (2003) · Human Gene Therapy · doi:10.1089/10430340360464660 · Cited by 194
Self-citation
Metadata
- Authors
- Pardridge, W. M.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2004-07
- Volume
- 4
- Issue
- 7
- Pages
- 1103-1113
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1989617912
- Cited by
- 104
- References
- 4
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous, non-viral RNAi gene therapy of brain cancer. https://app.cochat.ai/papers/10.1517/14712598.4.7.1103
- The paper
- Pardridge, W. M. (2004). Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.4.7.1103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.